Search research articles
Contact Us
Filters
Showing results (71-80 of 231) with videos related to
Page
of 24
Sort By:
Blood Neoplasia
|
August 12, 2025
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy
Suravi Raychaudhuri, Megan Othus, Mary-Elizabeth M Percival, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 8, 2020
Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm
Raffaele Palmieri, Megan Othus, Anna B Halpern, et al.
Haematologica
|
July 14, 2022
Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data
Megan Othus, Guillermo Garcia-Manero, John E Godwin, et al.
Blood Cancer Journal
|
May 3, 2025
Biobanking and consent to future biospecimen use among adults enrolled in SWOG trials from 2000 to 2024
Daniel J Olivieri, Alexis Berridge-Green, Megan Othus, et al.
Haematologica
|
March 22, 2015
Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia
Daisuke Araki, Megan Othus, Roland B Walter, et al.
Research Square
|
November 28, 2024
Relationship Between Age, Conditioning Intensity, and Outcome After Allografting in Adults Age ≥60 Years with AML
Phuong Vo, Brenda Sandmaier, Megan Othus, et al.
Leukemia
|
December 12, 2024
Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia
Corentin Orvain, Filippo Milano, Eduardo Rodríguez-Arbolí, et al.
Hemasphere
|
February 2, 2026
Immunophenotypic abnormality quantification refines multiparameter flow cytometry-based measurable residual disease testing in adults allografted for acute myeloid leukemia in morphologic remission
Calvin M Le, Xueyan Chen, Shunya Kodaira, et al.
Blood Advances
|
February 4, 2026
Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia: A Single Institution Experience Across Six Decades
Daniel J Olivieri, Megan Othus, Phuong T Vo, et al.
Leukemia
|
January 27, 2025
Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203
Megan Othus, Guillermo Garcia-Manero, Frederick R Appelbaum, et al.
Page
of 24
Search research articles
Search
Showing results (71-80 of 231) with videos related to
Sort By:
Page
of 24
Blood Neoplasia
|
August 12, 2025
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy
Suravi Raychaudhuri, Megan Othus, Mary-Elizabeth M Percival, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 8, 2020
Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm
Raffaele Palmieri, Megan Othus, Anna B Halpern, et al.
Haematologica
|
July 14, 2022
Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data
Megan Othus, Guillermo Garcia-Manero, John E Godwin, et al.
Blood Cancer Journal
|
May 3, 2025
Biobanking and consent to future biospecimen use among adults enrolled in SWOG trials from 2000 to 2024
Daniel J Olivieri, Alexis Berridge-Green, Megan Othus, et al.
Haematologica
|
March 22, 2015
Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia
Daisuke Araki, Megan Othus, Roland B Walter, et al.
Research Square
|
November 28, 2024
Relationship Between Age, Conditioning Intensity, and Outcome After Allografting in Adults Age ≥60 Years with AML
Phuong Vo, Brenda Sandmaier, Megan Othus, et al.
Leukemia
|
December 12, 2024
Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia
Corentin Orvain, Filippo Milano, Eduardo Rodríguez-Arbolí, et al.
Hemasphere
|
February 2, 2026
Immunophenotypic abnormality quantification refines multiparameter flow cytometry-based measurable residual disease testing in adults allografted for acute myeloid leukemia in morphologic remission
Calvin M Le, Xueyan Chen, Shunya Kodaira, et al.
Blood Advances
|
February 4, 2026
Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia: A Single Institution Experience Across Six Decades
Daniel J Olivieri, Megan Othus, Phuong T Vo, et al.
Leukemia
|
January 27, 2025
Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203
Megan Othus, Guillermo Garcia-Manero, Frederick R Appelbaum, et al.
Page
of 24